Showing posts with label Intersect ENT. Show all posts
Showing posts with label Intersect ENT. Show all posts

Sunday, April 1, 2018

Large Opportunities And High Expectations Battling It Out At Intersect ENT

The history of Intersect ENT (XENT) should look very familiar to long-term investors in the med-tech sector. This company came to the market all shiny and new in 2014 with an interesting, differentiated product for an underserved market (chronic sinusitis) that offered $1 billion-plus revenue potential. The stock more than doubled in its first year, but then the pace of revenue growth couldn't match what was laid out in the initial sell-side models and the shares lost almost two-thirds of their value.

Since the shares hit a late 2016 low, though, the company has been executing well. Although penetration/usage rates are slower than what was hoped for back in 2014, the pace of growth still isn't bad and the company is about to launch a new product that could add over $1 billion to its addressable market. A forward EV/revenue multiple of around 9x tells you the sort of growth expectations that are in place, but the underlying valuation isn't so unreasonable compared to the long-term opportunity.

Read the full article here:
Large Opportunities And High Expectations Battling It Out At Intersect ENT